CytomX Therapeutics, Inc.CTMXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| NOS. of Above Persons | 9.99% | 7.8M | ▲ +0.19pp | 2024-11-14 |
| Cormorant Global Healthcare Master Fund, LP | 7.38% | 5.8M | — | 2024-05-13 |
| The Vanguard Group | 7.32% | 4.9M | — | 2024-02-13 |
| Biotechnology Value Fund, L.P. | 7.00% | 5.7M | ▲ +1.60pp | 2024-11-14 |
| S.S. OR | 6.20% | 4.8M | ▲ +0.90pp | 2024-11-14 |
| Cormorant Asset Management, LP | 0.00% | 23.3K | — | 2024-11-14 |
Insider Transactions
Net 90d: −$1.23M · buys $0 / sells $1.23MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell (open market) | 31.5K | $6.42 | $202.3K |
| 2026-03-17 | Christopher Ogden | Chief Financial Officer | Sell (open market) | 19.3K | $6.42 | $124.1K |
| 2026-03-17 | Chu Yu-Waye | Chief Medical Officer | Sell (open market) | 21.3K | $6.42 | $136.7K |
| 2026-03-17 | McCarthy Sean A. | CEO | Sell (open market) | 119.0K | $6.42 | $764.1K |
| 2026-02-02 | Chu Yu-Waye | Chief Medical Officer | Grant | 75.0K | $0.00 | $0 |
| 2026-02-02 | Rachael Lester | Chief Business Officer | Grant | 20.0K | $0.00 | $0 |
| 2026-02-02 | BELVIN MARCIA | SVP, Chief Scientific Officer | Grant | 60.0K | $0.00 | $0 |
| 2026-02-02 | McCarthy Sean A. | CEO | Grant | 210.0K | $0.00 | $0 |
| 2026-02-02 | Christopher Ogden | Chief Financial Officer | Grant | 90.0K | $0.00 | $0 |
1–9 of 9